Industry news that matters to you.  Learn more

MDxHealth Licenses Biomarkers for Bladder Cancer to Predictive Biosciences

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has agreed to out-license certain DNA methylation biomarkers to Predictive Biosciences (Lexington, MA) for diagnostic applications in bladder cancer.

Instant Diagnoses via Lab-on-a-chip

Today, a blood sample whose protein content, genes and so on are to be read needs to be submitted to a series of complex processes, such as centrifugation, heat treatment, mixing with enzymes and concentration of disease markers. This means that samples are sent to central laboratories for analysis, and weeks may pass before the results are returned.

Epigenomics and Predictive Biosciences Extend Licensing Deal for Prostate Cancer Test

Epigenomics AG, the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced that they have extended their licensing agreement for the prostate cancer biomarker GSTP1, originally signed in April 2009. Under the terms of the original agreement, Predictive Biosciences had obtained rights to develop a prostate cancer test incorporating this well known DNA methylation biomarker and an option to license GSTP1 for commercialization of this test as a laboratory service in the United States. Based on strong continued progress in developing the test, Predictive Biosciences has now executed this option, triggering an undisclosed one-time license fee to Epigenomics. Epigenomics will also be entitled to royalties on future sales generated with Predictive Biosciences’ prostate cancer test, which is still in development.

Takeda and Sage Bionetworks Form CNS Disease Research Alliance

Takeda Pharmaceutical Company Limited, a global pharmaceutical company, and Sage Bionetworks, a new strategic nonprofit biomedical research organization, today announced that they have formed a four-year research alliance that will focus on discovering effective therapeutic targets for Central Nervous System (CNS) disease.

Pacific Biosciences Looks to Raise $200M through $16 per Share IPO

Next-gen sequencing firm Pacific Biosciences has priced its initial public offering (IPO) of 12,500,000 shares of common stock at $16 per share. The firm, which is going public today, has in addition offered its underwriters a 30-day option to purchase up to 1,875,000 shares at the IPO price, to cover any overallotments.